title: Current and future systemic treatment options in metastatic pancreatic cancer.
abstract: Although pancreatic adenocarcinoma is the fourth leading cause of cancer death, only modest improvement has been observed in the past two decades, single agent gemcitabine has been the only standard treatment in patients with advanced disease. Recently newer agents such as nab-paclitaxel, nimotuzumab and regimens such as FOLFIRINOX have been shown to have promising activity being superior to gemcitabine as a single agent. With better understanding of tumour biology coupled with the improvements in targeted and immunotherapies, there is increasing expectation for better response rates and extended survival in pancreatic cancer.
authors.affiliation: 1 Department of Medical Oncology, Izmir University Medical Park Hospital, Izmir, Turkey ; 2 Department of Medical Oncology, Hacettepe University, Institute of Oncology, Ankara, Turkey.
authors.forename: Cagatay
authors.initials: C
authors.lastname: Arslan
authors.affiliation: 1 Department of Medical Oncology, Izmir University Medical Park Hospital, Izmir, Turkey ; 2 Department of Medical Oncology, Hacettepe University, Institute of Oncology, Ankara, Turkey.
authors.forename: Suayib
authors.initials: S
authors.lastname: Yalcin
keywords: FOLFINOX; Pancreatic cancer treatment; immunotherapy; nabpaclitaxel; targeted therapy
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3605-10
references.pmid: 20606093
references.citation: Cancer. 2012 May 15;118(10):2674-81
references.pmid: 21935914
references.citation: J Clin Oncol. 2007 May 20;25(15):1960-6
references.pmid: 17452677
references.citation: Br J Cancer. 2006 Dec 4;95(11):1474-82
references.pmid: 17060934
references.citation: Cell. 1988 May 20;53(4):549-54
references.pmid: 2453289
references.citation: Invest New Drugs. 2012 Apr;30(2):779-86
references.pmid: 21170669
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1291-5
references.pmid: 18316546
references.citation: Cell Cycle. 2005 Sep;4(9):1176-8
references.pmid: 16123586
references.citation: J Clin Oncol. 2009 May 1;27(13):2231-7
references.pmid: 19307500
references.citation: J Clin Oncol. 2007 Dec 10;25(35):5609-15
references.pmid: 18065733
references.citation: J Biol Chem. 1988 Nov 25;263(33):17755-62
references.pmid: 2460463
references.citation: Ann Surg. 2007 Aug;246(2):173-80
references.pmid: 17667493
references.citation: J Immunother. 2013 Sep;36(7):382-9
references.pmid: 23924790
references.citation: J Clin Oncol. 2010 Jan 20;28(3):375-9
references.pmid: 20008645
references.citation: Science. 2011 Mar 25;331(6024):1612-6
references.pmid: 21436454
references.citation: J Transl Med. 2007 Nov 26;5:60
references.pmid: 18039393
references.citation: J Clin Oncol. 2011 Dec 1;29(34):4548-54
references.pmid: 21969517
references.citation: Eur J Cancer. 2005 Nov;41(17):2620-9
references.pmid: 16239105
references.citation: Lancet Oncol. 2011 Mar;12(3):256-62
references.pmid: 21306953
references.citation: Semin Cancer Biol. 2012 Oct;22(5-6):455-61
references.pmid: 22627188
references.citation: Cancer Immunol Immunother. 2005 Mar;54(3):254-64
references.pmid: 15372205
references.citation: Am J Clin Oncol. 2014 Apr;37(2):194-200
references.pmid: 22643564
references.citation: Cancer Treat Rev. 2012 Nov;38(7):843-53
references.pmid: 22226241
references.citation: JOP. 2011 Jul 08;12(4):316-21
references.pmid: 21737886
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: N Engl J Med. 2011 May 12;364(19):1817-25
references.pmid: 21561347
references.citation: Expert Opin Ther Targets. 2010 May;14(5):541-52
references.pmid: 20392166
references.citation: J Clin Oncol. 2010 Nov 20;28(33):4877-83
references.pmid: 20921468
references.citation: Clin Cancer Res. 2011 Sep 1;17(17):5793-800
references.pmid: 21742805
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):510-23
references.pmid: 22128301
references.citation: Ann Surg. 2011 Feb;253(2):328-35
references.pmid: 21217520
references.citation: Int J Gastrointest Cancer. 2002;32(1):1-6
references.pmid: 12630764
references.citation: Expert Rev Anticancer Ther. 2012 Oct;12(10):1327-36
references.pmid: 23176620
references.citation: Pancreas. 2013 Jan;42(1):32-6
references.pmid: 22699203
references.citation: Pancreas. 2012 Mar;41(2):195-205
references.pmid: 21792083
references.citation: Int J Cancer. 2001 May 1;92(3):441-50
references.pmid: 11291084
references.citation: Clin Exp Med. 2012 Sep;12(3):173-80
references.pmid: 21932124
references.citation: Br J Cancer. 2002 Jul 15;87(2):161-7
references.pmid: 12107836
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):342-6
references.pmid: 17301269
references.citation: MedGenMed. 2005 Jun 29;7(2):60
references.pmid: 16369438
references.citation: Cancer Cell. 2012 Mar 20;21(3):418-29
references.pmid: 22439937
references.citation: Cancer Res. 1994 Jun 1;54(11):2856-60
references.pmid: 7514493
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1430-8
references.pmid: 15084616
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5513-8
references.pmid: 19858379
references.citation: Eur J Cancer. 2011 Jul;47(11):1676-81
references.pmid: 21565490
references.citation: Ann Oncol. 2013 Jul;24(7):1792-1801
references.pmid: 23448807
references.citation: Invest New Drugs. 2012 Feb;30(1):382-6
references.pmid: 20803052
references.citation: J Clin Oncol. 2009 Jan 10;27(2):193-8
references.pmid: 19047305
references.citation: Nat Rev Cancer. 2007 Aug;7(8):573-84
references.pmid: 17625587
references.citation: Cancer Biol Ther. 2005 Sep;4(9):934-6
references.pmid: 16251802
references.citation: Am J Gastroenterol. 1998 Oct;93(10):1967-71
references.pmid: 9772067
references.citation: Eur J Cancer. 2014 Aug;50(12):2072-81
references.pmid: 24915778
references.citation: Cancer J. 2012 Nov-Dec;18(6):642-52
references.pmid: 23187853
references.citation: Clin Cancer Res. 2012 Aug 15;18(16):4266-76
references.pmid: 22896693
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1145-53
references.pmid: 20100965
references.citation: Oncologist. 2013;18(10):1091-2
references.pmid: 24072218
references.citation: BMC Cancer. 2008 Mar 28;8:82
references.pmid: 18373843
references.citation: Dig Dis Sci. 2007 Aug;52(8):1964-72
references.pmid: 17420942
references.citation: Nat Rev Cancer. 2004 Oct;4(10):814-9
references.pmid: 15510162
references.citation: J Clin Oncol. 1997 Jun;15(6):2403-13
references.pmid: 9196156
references.citation: Ann Oncol. 2012 Nov;23(11):2799-2805
references.pmid: 22771827
references.citation: Mol Cancer Ther. 2010 Nov;9(11):3052-64
references.pmid: 20978165
references.citation: N Engl J Med. 2010 Apr 29;362(17):1605-17
references.pmid: 20427809
references.citation: Gut. 2011 Jun;60(6):861-8
references.pmid: 20966025
references.citation: N Engl J Med. 2009 Sep 17;361(12):1164-72
references.pmid: 19726763
references.citation: Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S68-75
references.pmid: 10396302
references.citation: Cancer Res. 1996 Dec 1;56(23):5360-4
references.pmid: 8968085
references.citation: Clin Cancer Res. 2012 May 15;18(10):2723-5
references.pmid: 22465829
references.citation: N Engl J Med. 2013 Oct 31;369(18):1691-703
references.pmid: 24131140
references.citation: Cancer Res. 2005 Nov 15;65(22):10555-61
references.pmid: 16288048